-
公开(公告)号：US10076529B1
公开(公告)日：2018-09-18
申请号：US15068379
申请日：2016-03-11
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure Le Ny , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： A61K31/635 , A61K31/426 , A61K31/454 , A61K31/444 , A61K31/496 , A61K31/4709 , A61K31/4409 , A61K31/47 , A61K31/5377 , A61K31/501 , A61K31/55 , G06F19/12 , A61K31/4545
CPC分类号： A61K31/635 , A61K31/426 , A61K31/4409 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K31/55 , C07D215/52 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D498/04 , G16B5/00
摘要： Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5′ and 3′-UTR sequences of the viral genome.
-
2.发明授权公开(公告)号：US09422291B2
公开(公告)日：2016-08-23
申请号：US14103267
申请日：2013-12-11
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure LeNy , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： A01N43/90 , A61K31/519 , A01N37/18 , A61K38/00 , A61P31/12 , C07D487/04
CPC分类号： A61K31/519 , C07D487/04
摘要： Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
摘要翻译： 预期抗病毒组合物和方法在治疗和预防甲型流感病毒方面特别有效。 还提供了用于鉴定具有抗病毒性质的小分子化合物的细胞测定法，特别是涉及在独立于其它甲型流感病毒组分的哺乳动物细胞中检测甲型流感病毒RNA依赖性RNA聚合酶活性。 优选的测定允许鉴定不破坏正常细胞活性的病毒复制抑制剂。
-
公开(公告)号：US09463184B2
公开(公告)日：2016-10-11
申请号：US14442392
申请日：2013-11-13
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Justin Golovato , Patrick Soon-Shiong , Anne-Laure Le Ny , Oleksandr Buzko
IPC分类号： A01N43/76 , A61K31/42 , A01N43/08 , A61K31/34 , A01N43/20 , A01N43/24 , A61K31/335 , A61K31/423 , A61K31/05 , A61K31/12 , A61K31/365 , A61K31/404 , A61K31/407 , A61K33/24 , A61K9/00 , A61K47/06 , A61K47/10 , A61K31/341 , A61K31/16 , A61K31/66
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/05 , A61K31/12 , A61K31/16 , A61K31/341 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/423 , A61K31/66 , A61K33/24 , A61K39/085 , A61K47/06 , A61K47/10 , A61K2039/54 , A61K2039/55511 , A61K2039/57
摘要： Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
摘要翻译： 钙通量激动剂用于增强TLR或NOD介导的刺激，从而增加宿主的免疫应答并减少愈合时间。 优选的钙通量激动剂包括Ca 2+离子载体和SERCA抑制剂，并且以协同量使用其中存在TLR或NOD受体的配体。
-
4.发明授权公开(公告)号：US09315464B1
公开(公告)日：2016-04-19
申请号：US14170353
申请日：2014-01-31
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure Le Ny , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： C07D215/52 , C07D401/12 , C07D401/04 , C07D405/14 , C07D413/12 , C07D413/14 , C07D401/14 , G06F19/12 , C07D498/04 , C07D417/12 , C07D417/14
CPC分类号： C07D215/52 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D498/04 , G06F19/12
摘要： Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5′ and 3′-UTR sequences of the viral genome.
摘要翻译： 考虑到对RNA病毒，特别是正粘病毒具有显着抗病毒作用的组合物，化合物和方法，并靶向由病毒基因组的5'和3'-UTR序列形成的病毒启动子。
-
公开(公告)号：US20170128450A1
公开(公告)日：2017-05-11
申请号：US15213049
申请日：2016-07-18
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure LeNy , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： A61K31/519
CPC分类号： A61K31/519 , C07D487/04
摘要： Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
-
公开(公告)号：US20150297572A1
公开(公告)日：2015-10-22
申请号：US14442392
申请日：2013-11-13
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Justin Golovato , Patrick Soon-Shiong , Anne-Laure Le Ny , Oleksandr Buzko
IPC分类号： A61K31/423 , A61K31/365 , A61K9/00 , A61K31/341
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/05 , A61K31/12 , A61K31/16 , A61K31/341 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/423 , A61K31/66 , A61K33/24 , A61K39/085 , A61K47/06 , A61K47/10 , A61K2039/54 , A61K2039/55511 , A61K2039/57
摘要： Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
摘要翻译： 钙通量激动剂用于增强TLR或NOD介导的刺激，从而增加宿主的免疫应答并减少愈合时间。 优选的钙通量激动剂包括Ca 2+离子载体和SERCA抑制剂，并且以协同量使用其中存在TLR或NOD受体的配体。
-
公开(公告)号：US09987282B2
公开(公告)日：2018-06-05
申请号：US15213049
申请日：2016-07-18
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure LeNy , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： A61K31/519
CPC分类号： A61K31/519 , C07D487/04
摘要： Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
-
公开(公告)号：US20170128568A1
公开(公告)日：2017-05-11
申请号：US15264947
申请日：2016-09-14
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Justin Golovato , Patrick Soon-Shiong , Anne-Laure Le Ny , Oleksandr Buzko
IPC分类号： A61K39/39 , A61K39/085
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/05 , A61K31/12 , A61K31/16 , A61K31/341 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/423 , A61K31/66 , A61K33/24 , A61K39/085 , A61K47/06 , A61K47/10 , A61K2039/54 , A61K2039/55511 , A61K2039/57
摘要： Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
-
公开(公告)号：US10350225B1
公开(公告)日：2019-07-16
申请号：US16110634
申请日：2018-08-23
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure Le Ny , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： C07D417/12 , A61K31/635 , A61K31/55 , A61K31/501 , A61K31/5377 , A61K31/47 , A61K31/4409 , A61K31/4709 , A61K31/496 , A61K31/4545 , A61K31/444 , A61K31/426 , A61K31/454 , G16B5/00
摘要： Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5′ and 3′-UTR sequences of the viral genome.
-
公开(公告)号：US20180086752A1
公开(公告)日：2018-03-29
申请号：US15563813
申请日：2016-04-01
发明人： Shahrooz Rabizadeh , Kayvan Niazi , Sasha Buzko , Paul Weingarten , Heather McFarlane , Anna Juncker-Jensen , Justin Golovato , Patrick Soon-Shiong , Chunlin Tao , David Ho
IPC分类号： C07D417/14 , C07D417/12 , C07F9/6558 , C07D471/06 , C07D417/04
CPC分类号： C07D417/14 , A61K31/427 , A61P35/00 , C07D277/46 , C07D417/04 , C07D417/12 , C07D471/06 , C07F9/65583
摘要： Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.011 秒)
